Clinical Trial Detail

NCT ID NCT02066181
Title Sorafenib Tosylate in Treating Patients With Desmoid Tumors or Aggressive Fibromatosis
Recruitment Active, not recruiting
Gender both
Phase Phase III
Variant Requirements No
Sponsors National Cancer Institute (NCI)
Indications

sarcoma

Therapies

Sorafenib

Age Groups: adult

No variant requirements are available.